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Abstract
Background: The transcription factor NFAT5/TonEBP regulates the response of mammalian cells to
hypertonicity. However, little is known about the physiopathologic tonicity thresholds that trigger its
transcriptional activity in primary cells. Wilkins et al. recently developed a transgenic mouse carrying a
luciferase reporter (9xNFAT-Luc) driven by a cluster of NFAT sites, that was activated by calcineurin-
dependent NFATc proteins. Since the NFAT site of this reporter was very similar to an optimal NFAT5
site, we tested whether this reporter could detect the activation of NFAT5 in transgenic cells.
Results: The 9xNFAT-Luc reporter was activated by hypertonicity in an NFAT5-dependent manner in
different types of non-transformed transgenic cells: lymphocytes, macrophages and fibroblasts. Activation
of this reporter by the phorbol ester PMA plus ionomycin was independent of NFAT5 and mediated by
NFATc proteins. Transcriptional activation of NFAT5 in T lymphocytes was detected at hypertonic
conditions of 360–380 mOsm/kg (isotonic conditions being 300 mOsm/kg) and strongly induced at 400
mOsm/kg. Such levels have been recorded in plasma in patients with osmoregulatory disorders and in mice
deficient in aquaporins and vasopressin receptor. The hypertonicity threshold required to activate NFAT5
was higher in bone marrow-derived macrophages (430 mOsm/kg) and embryonic fibroblasts (480 mOsm/
kg). Activation of the 9xNFAT-Luc reporter by hypertonicity in lymphocytes was insensitive to the ERK
inhibitor PD98059, partially inhibited by the PI3-kinase inhibitor wortmannin (0.5 µM) and the PKA
inhibitor H89, and substantially downregulated by p38 inhibitors (SB203580 and SB202190) and by
inhibition of PI3-kinase-related kinases with 25 µM LY294002. Sensitivity of the reporter to FK506 varied
among cell types and was greater in primary T cells than in fibroblasts and macrophages.
Conclusion:  Our results indicate that NFAT5 is a sensitive responder to pathologic increases in
extracellular tonicity in T lymphocytes. Activation of NFAT5 by hypertonicity in lymphocytes was
mediated by a combination of signaling pathways that differed from those required in other cell types. We
propose that the 9xNFAT-Luc transgenic mouse model might be useful to study the physiopathological
regulation of both NFAT5 and NFATc factors in primary cells.
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Background
NFAT5/TonEBP belongs to the Rel family of transcription
factors, which also comprises NF-κB and the calcineurin-
dependent NFATc proteins (NFAT1/NFATc2, NFAT2/
NFATc1, NFAT3/NFATc4, NFAT4/NFATc3) [1,2]. Rel pro-
teins have in common a conserved DNA binding domain,
but do not display recognizable similarities outside of it.
The DNA binding domain of NFAT5 is considered a
hybrid between that of NF-κB and NFATc proteins, since
it is a constitutive dimer, structurally similar to NF-κB, but
has NFATc-like DNA sequence specificity, with its optimal
binding site being a 5'-TGGAAA(C/A/T)A(T/A)-3' motif,
in which the NFATc cognate element is 5'-(T/A/
C)GGAA(A/G)-3' [2-4]. NFATc and NFAT5 differ substan-
tially in their mechanisms of activation and biological
function. NFATc proteins are characteristically activated
by the phosphatase calcineurin in response to increases in
intracellular calcium concentration [5,6], whereas NFAT5
is activated by hypertonicity [1]. Activation of NFAT5 is
regulated by different kinases, such as the stress-activated
kinase p38, Fyn [7], PKA [8], ERK [9], the PI3-kinase-
related kinase (PIKK) ATM [10,11], and phosphoinositide
3-kinase (PI3-kinase) [11]. p38 has been shown to regu-
late NFAT5 in some cell types but not in others [7,12].
NFATc proteins play fundamental roles in the immune,
nervous and cardiovascular systems (reviewed in [13-
15]). NFAT5 allows mammalian cells to adapt to hyperto-
nicity [16,17], by inducing the expression of osmoprotec-
tive proteins, such as aldose reductase (AR), Na+/Cl--
coupled betaine/γ-aminobutyric acid transporter (BGT1),
Na+-dependent myo-inositol transporter (SMIT), Na+ and
Cl--dependent taurine transporter (TauT), UT-A urea
transporter, and Hsp70 (reviewed in [18] and [19]).
NFAT5-deficient mice suffer severe atrophy of the renal
medulla, a naturally hypertonic environment, and
impaired lymphocyte function [16,17].
The osmoresponsive function of NFAT5 has been docu-
mented in diverse cell types, such as lymphocytes [3,20],
embryonic fibroblasts [16,17], kidney cells [16,21], neu-
rons [22,23], and cell lines of different lineages [10].
However, little is known about tonicity thresholds (phys-
iologic or pathologic) at which NFAT5 is activated in spe-
cific types of primary cells. In this regard, a transgenic
mouse model with an integrated NFAT5-responsive
reporter would facilitate the analysis of its transcriptional
regulation in primary cells and tissues. An NFAT-luciferase
(9xNFAT-Luc) transgenic mouse carrying 9 copies of an
NFAT site (5'-TGGAAAATT-3') positioned 5' to the mini-
mal promoter of the α-myosin heavy chain gene was
developed by Wilkins et al., who studied the role of the
calcineurin-NFATc pathway in cardiac hypertrophy [24].
As described in the original article, luciferase activity was
detectable in most organs and was highest in the brain,
kidney and heart, indicating that the reporter was func-
tional in different types of tissues. Since the NFAT site
used in the reporter construct almost coincided with an
optimal binding site for NFAT5 (5'-TGGAAAAAT-3'), we
wondered whether it could be activated by this factor.
In this work we show that the 9xNFAT-Luc reporter is acti-
vated by NFAT5 in response to hypertonicity in transgenic
primary T lymphocytes, macrophages and mouse embryo
fibroblasts (MEF), and by NFATc proteins in response to
calcineurin activation. Activation of NFAT5 in lym-
phocytes was detected in response to hypertonicity levels
in the range measured in plasma in patients and animal
models with osmoregulatory disorders. Activation of
NFAT5 transcriptional activity by hypertonicity was sub-
stantially downregulated by the p38 inhibitors SB203580
and SB202190, and by inhibition of PIKK with 25 µM
LY294002. The reporter was partially sensitive to the cal-
cineurin inhibitor FK506, the PI3-kinase inhibitor wort-
mannin (0.5 µM), and the protein kinase A inhibitor H89,
but was not inhibited by the ERK inhibitor PD98059.
These results, together with others in the literature, suggest
that activation of NFAT5 by hypertonicity involves differ-
ent combinations of signaling pathways in different cell
types. Our results indicate that 9xNFAT-Luc mice might
constitute a useful tool to study the regulation of both
NFAT5 and NFATc proteins and the effect of pharmaco-
logical modulators in different types of primary cells.
Results
Activation of the 9xNFAT-Luc reporter by NFAT5 or 
NFATc proteins in a stimulus-specific manner
We observed that the 9xNFAT-Luc reporter was compara-
bly activated by hypertonicity or PMA plus ionomycin
(P+I) in the human T lymphocyte cell line Jurkat (Figure
1A). Activation by P+I was suppressed by the calcineurin
inhibitor FK506, whereas induction by hypertonicity was
not. Hypertonicity-induced activation was downregulated
by > 60% in cells transfected with the isolated dimeriza-
tion domain of NFAT5 (DD5), which inhibits NFAT5 but
not NFATc proteins [3], whereas activation by P+I was not
significantly inhibited (Figure 1B). The VIVIT peptide,
which disrupts the binding of calcineurin to NFATc pro-
teins [25], prevented the activation of the reporter by P+I
without affecting its induction by hypertonicity (Figure
1B). The 9xNFAT-Luc reporter was activated by hyperto-
nicity levels between 380 to 530 mOsm/kg, comparably
to a widely used NFAT5-dependent reporter driven by the
enhancer of the aldose reductase gene [3,26] (Figure 1C).
These results indicated that the 9xNFAT-Luc reporter
could be activated by distinct types of stimuli: hypertonic-
ity via NFAT5, and PMA plus ionomycin via the cal-
cineurin-dependent NFATc proteins.
In order to conclusively confirm that the 9xNFAT-Luc
reporter was activated by NFAT5 under hypertonic condi-BMC Molecular Biology 2008, 9:13 http://www.biomedcentral.com/1471-2199/9/13
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tions, we bred NFAT5+/- mice [16] into the 9xNFAT-Luc
transgenic background to obtain 9xNFAT-Luc+/NFAT5-/-
mice. We derived mouse embryo fibroblasts (MEF), and
also analyzed mature T cells and bone marrow-derived
macrophages from several independent NFAT5-/-  adult
mice. As shown in Figure 2A, hypertonicity activated the
9xNFAT-Luc reporter in NFAT5+/+ MEF, but not in NFAT5-
/- cells. Both cell types showed a comparable response to
P+I, which was suppressed by FK506. Activation of the
reporter by hypertonicity in NFAT5+/+ MEF was partially
inhibited (30%) by FK506. Transfection of an NFAT5
expression vector in NFAT5-/-  MEF reconstituted their
responsiveness to hypertonicity (Figure 2B). Results
obtained with 9xNFAT-Luc transgenic T cells derived from
NFAT5+/+ and NFAT5-/- mice confirmed that activation of
the reporter by hypertonicity was severely impaired in
NFAT5-/- cells, whereas activation by P+I was independent
of NFAT5 (Table 1). Hypertonicity-induced activation of
the 9xNFAT-Luc reporter was variably inhibited by FK506
in T lymphocytes. We also noticed that hypertonicity
induced a weak activation of the reporter in NFAT5-/- cells,
which was also partially inhibited by FK506. It has been
Activation of the 9xNFAT-luc reporter by NFATc or NFAT5 Figure 1
Activation of the 9xNFAT-luc reporter by NFATc or NFAT5. A) Jurkat T cells transfected with the 9xNFAT-Luc 
reporter were stimulated with PMA plus ionomycin (P+I) or cultured in hypertonic medium (500 mOsm/kg) without or with 
FK506 during 24 hours. Luciferase activity is represented as relative light units per second (RLU) after normalization with 
Renilla and endogenous lactate dehydrogenase. Mean ± S.D of four independent experiments is shown. B) 9xNFAT-Luc and 
vectors encoding GFP, the NFAT5-inhibitory dimerization domain (DD5-GFP) or the NFATc-inhibitory peptide VIVIT (VIVIT-
GFP) were transfected in Jurkat T cells. Cells were treated during 24 hours with PMA plus ionomycin or hypertonicity (500 
mOsm/kg) in the absence or presence of FK506. Mean ± S.D of three independent experiments is shown. N.S.: non statistically 
significant. C) Jurkat T cells transfected with the 9xNFAT-Luc reporter or the ORE-luc reporter were exposed to increasingly 
hypertonic media in the presence of FK506, or stimulated with PMA plus ionomycin without FK506. Mean ± S.D of three inde-
pendent experiments is shown.
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recently shown that NFATc1 can be activated by hyperto-
nicity [27], and thus it is possible that the residual activity
induced by hypertonic stimulation in NFAT5-/- T cells
could be due to NFATc proteins. Nonetheless, our overall
results in primary T lymphocytes, macrophages (see
below), MEF and Jurkat T cells showed that activation of
the 9xNFAT-Luc reporter by hypertonicity was predomi-
nantly attributable to NFAT5, while other factors made a
much lesser contribution to this stimulus. On the other
hand, we did not observe significant contribution of
NFAT5 to the activation of the 9xNFAT-Luc reporter by
P+I.
Hypertonicity threshold for NFAT5 activation
Studies on hypertonic stress responses in different types of
mammalian cells usually utilize hypertonicity levels of
500 mOsm/kg or higher, although it is poorly understood
where cells might be exposed to such elevated hypertonic-
ity levels besides the renal medulla. Physiologic osmolal-
ity values in plasma, brain and lung in mice are close to
300 mOsm/kg, and between 330–340 mOsm/kg in thy-
mus, spleen and liver [17]. In humans, normal plasma
osmolality is ~290 mOsm/kg, but can rise to the range of
380 to 430 mOsm/kg in cases of severe hypernatremia
[28], salt poisoning in infants [29], adipsic disorders with
impairment of thirst perception [30-32], and renal
pathologies [33,34]. Constitutively elevated plasma tonic-
ity (~400 mOsm/kg) has been reported in mice deficient
in V2 vasopressin receptor [35], and in mice with congen-
ital progressive hydronephrosis caused by a mutation in
aquaporin-2 [36]. In aquaporin-1-deficient mice, plasma
tonicity can reach 517 mOsm/kg after 36 hours of water
deprivation, despite which these can survive if water is
administered to them again [37]. Elevation of the tonicity
in plasma would expose different tissues to hypertonic
stress and might activate NFAT5, as shown in rats where
an acute rise of plasma osmolality to 420 mOsm/kg trig-
gered a rapid increase in expression and nuclear accumu-
lation of NFAT5 in neurons [22].
Titration of the responsiveness of the 9xNFAT-Luc
reporter to hypertonicity in the T cell line Jurkat showed
that the reporter was significantly activated by hypertonic-
ity levels of ≥ 380 mOsm/kg (Figure 1C). Proliferating T
cells derived from splenocytes stimulated during 3 days
with the mitogen concanavalin A (ConA) plus IL2 showed
calcineurin-independent activation of the reporter at 430
mOsm/kg (Figure 3A). In the same type of cells, induction
of NFAT5 expression was detected at lower tonicity values
(330 mOsm/kg) than the activation of the reporter. In
these experiments, stimulation with hypertonicity was
done in the presence of the calcineurin inhibitor FK506 to
prevent any potential contribution of NFATc proteins.
When we measured the activity of the reporter in freshly
isolated thymocytes and splenocytes, we detected its acti-
vation only in response to P+I, but not with hypertonicity
(Figures 3B and 3C). These results suggested that optimal
NFAT5-mediated activation of the transgenic reporter in
lymphocytes depended on their activation state. In agree-
ment with this, we found that a 24-hour stimulation of T
Unresponsiveness of the 9xNFAT-Luc reporter to hypertonicity in NFAT5-deficient cells Figure 2
Unresponsiveness of the 9xNFAT-Luc reporter to hypertonicity in NFAT5-deficient cells. A) NFAT5+/+ and 
NFAT5-/- MEF were transfected with the 9xNFAT-Luc reporter and stimulated with PMA plus ionomycin or hypertonicity (460 
mOsm/kg), with or without FK506, during 24 hours. Mean ± S.D of three independent experiments is shown. B) NFAT5-/- MEF 
were transfected with the 9xNFAT-Luc reporter and an empty vector (pBSK(+)) or an NFAT5 expression vector. Cells were 
stimulated with PMA plus ionomycin or hypertonicity (460 mOsm/kg), with or without FK506, during 24 hours. Mean ± S.E.M 
of three independent experiments is shown.
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cells with mitogens conferred them the ability to respond
to hypertonicity levels of 380 mOsm/kg (Figure 3C).
Next, we analyzed whether the responsiveness of the
reporter varied at different time points after T cells had
been stimulated with mitogens. As shown in Figure 4A
and Table 2, the response to hypertonicity was strongest
when cells had been stimulated with mitogens for one
day. In these cells, activation of the 9xNFAT-Luc reporter
was robustly induced at 380 and 400 mOsm/kg, and was
even detectable at 360 mOsm/kg in some of the experi-
ments. The intensity of the response became weaker in T
cells that had been cultured during 48 hours or longer
(Figure 4A and Table 2). We also found that lymphocytes
showed a lower hypertonicity threshold for NFAT5 activa-
tion than bone marrow-derived macrophages and MEF.
As shown in Figure 4B, NFAT5-dependent activation of
the 9xNFAT-Luc reporter in macrophages was observed at
430 mOsm/kg. It was noticeable that hypertonicity-
induced activation of this reporter was insensitive to
FK506 in macrophages. Activation of the reporter in MEF
required a higher hypertonicity threshold (480 mOsm/
kg) (Figure 4C).
Sensitivity of NFAT5 transcriptional activity to 
pharmacological inhibitors
NFAT5 is fundamental in the adaptation of mammalian
cells to osmotic stress, and the regulation of its transcrip-
tional function by signaling pathways in primary, non-
transformed cells, has not been fully elucidated. We ana-
lyzed the transcriptional response to hypertonicity in T
cells treated with inhibitors of signaling pathways that
had been reported to regulate NFAT5 in other cell types.
As shown in Figure 5A, activation of the 9xNFAT-Luc
reporter was downregulated by the p38 inhibitors
SB203580 and SB202190 (both at 10 µM), and by inhibi-
tion of PIKK with 25 µM LY294002. The reporter was
insensitive to the ERK inhibitor PD98059 (10 µM), and
partially inhibited by the calcineurin inhibitor FK506
(100 nM), the PI3-kinase inhibitors wortmannin (0.5
µM) and LY294002 (1 µM), and the protein kinase A
inhibitor H89 (2 µM). In the same type of experiment, 25
µM LY294002 also caused a mild inhibition of NFAT5
expression (Figure 5A). The JNK inhibitor SP600125 (10
µM) yielded inconsistent results, and we only observed a
30% inhibition of the reporter in one of three independ-
ent experiments (not shown).
Table 1: Impaired activation of endogenous 9xNFAT-Luc transgenic reporter by hypertonicity in NFAT5-deficient lymphocytes.
9xNFAT-Luc reporter activity (RLU)
Experiment # 1 Experiment # 2 Experiment # 2
NFAT5 +/+ NFAT5 -/- NFAT5 +/+ NFAT5 -/- NFAT5 +/+ NFAT5 -/-
8-hour stimulation
300 mOsm/kg (isotonic) - FK506 19 25 45 19 16 16
+  F K 5 0 6 1 11 31 81 6 7 8
430 mOsm/kg (hypertonic) - FK506 1026 117 825 191 387 27
+ FK506 720 83 1316 13 579 24
480 mOsm/kg (hypertonic) - FK506 12616 540 5677 42 10901 273
+ FK506 19543 435 2894 51 7403 102
PMA+ ionomycin (isotonic) - FK506 2445 10087 2080 2494 1726 6364
+  F K 5 0 6 2 41 93 43 13 7 1 5 8
24-hour stimulation
300 mOsm/kg (isotonic) - FK506 21 21 21 20 19 33
+  F K 5 0 6 1 01 51 41 51 21 0
430 mOsm/kg (hypertonic) - FK506 1351 188 297 239 348 102
+ FK506 550 122 254 129 388 73
480 mOsm/kg (hypertonic) - FK506 6930 359 1742 224 7267 245
+ FK506 1507 232 1111 129 3977 129
PMA+ ionomycin (isotonic) - FK506 1100 2516 791 825 418 1775
+ FK506 15 17 16 8 30 30
Luciferase activity was measured in proliferating transgenic 9xNFAT-Luc T cells derived from littermate NFAT5+/+ and NFAT5-/- mice after 
stimulation with hypertonic medium or PMA plus ionomycin, in the absence or presence of 100 nM FK506. Luciferase activity is represented as 
relative light units per second (RLU) after normalization with endogenous lactate dehydrogenase.BMC Molecular Biology 2008, 9:13 http://www.biomedcentral.com/1471-2199/9/13
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Experiments in MEF showed that activation of the
9xNFAT-Luc reporter was also prevented by SB203580
and LY294002 (Figure 5B). In these cells, SB203580 par-
tially reduced the accumulation of NFAT5 in response to
hypertonicity, while 25 µM LY294002 caused a substan-
tial inhibition of NFAT5 expression. These results revealed
that LY294002-sensitive kinases regulated both the tran-
scriptional activation of NFAT5 and its expression in
response to hypertonicity in different cell types.
Discussion
We show that the 9xNFAT-Luc reporter integrated in trans-
genic cells is activated by endogenous NFAT5 in response
to hypertonicity and by NFATc proteins in response to cal-
cineurin activation. A previous report had shown that a
chimeric reporter with NFAT5 sites inserted into the min-
imal IL2 promoter could be activated by NFAT5 in
response to hypertonicity as well as PMA plus ionomycin
in Jurkat T cells [38], suggesting that this factor might reg-
Activation of the transgenic 9xNFAT-Luc reporter in fresh and mitogen-activated lymphocytes Figure 3
Activation of the transgenic 9xNFAT-Luc reporter in fresh and mitogen-activated lymphocytes. A) Proliferating 
transgenic 9xNFAT-Luc T cells were exposed to increasingly hypertonic media in the presence of FK506, or stimulated with 
PMA plus ionomycin during 24 hours. Left panel: luciferase activity (RLU) shown is the mean ± S.E.M of five independent exper-
iments. Right panel: NFAT5 and pyruvate kinase (protein loading control) were detected by Western blotting. One represent-
ative experiment is shown out of three performed independently. B) Luciferase activity in 9xNFAT-Luc transgenic thymocytes 
exposed to increasingly hypertonic media in the presence of FK506, or stimulated with PMA plus ionomycin during 24 hours. 
Mean ± S.E.M of three independent experiments is shown. C) Luciferase activity in 9xNFAT-Luc transgenic splenocytes stimu-
lated during 24 hours with hypertonicity or PMA plus ionomycin, either immediately after their purification, or after a 24-hour 
preactivation with concanavalin A plus IL2. One representative experiment is shown out of three performed independently.
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ulate certain promoters in response to non-hypertonic
stimuli. Our results in primary mouse lymphocytes, mac-
rophages, MEF and Jurkat cells show a remarkable selec-
tivity in the activation of the 9xNFAT-Luc reporter by
NFAT5 in response to hypertonicity, and by NFATc pro-
teins in response to PMA plus ionomycin. These experi-
ments indicate that the specific recruitment of either
NFATc or NFAT5 to DNA sites to which both factors can
bind may be determined by the type of stimulus. This
finding is in line with work by the Goldfeld laboratory,
who showed that some sites in the TNFα promoter and
the LTR of HIV could recruit both NFAT5 and NFATc
[39,40], and that occupancy of the site by either type of
transcription factor depended on the stimulus. Hyperto-
nicity-mediated activation of the 9xNFAT-Luc reporter
was variably inhibited by FK506 in primary T cells and
MEF, although not in macrophages and Jurkat cells, sug-
gesting that calcineurin can modulate the hypertonic
stress response in some cell types. This observation is con-
sistent with a recent report showing that calcineurin was a
positive regulator of both NFATc1 and NFAT5 in the acti-
vation of the aquaporin 2 promoter by hypertonicity in
murine collecting duct cells [27]. Altogether, results from
previous work [3,27,38], and ours here indicate that cal-
cineurin might enhance the activation of NFAT5 by hyper-
tonicity in some cell types, although it is not generally
essential for its function, in contrast to the strict require-
ment of this phosphatase in the activation of NFATc pro-
teins.
The variable dependence of NFAT5 transcriptional activity
on calcineurin in different cell types would need to be
considered when using the 9xNFAT-Luc mice to study the
activation of NFAT5 and NFATc proteins in vivo or in pri-
mary cultures from different organs. The use of cal-
cineurin inhibitors in cell culture experiments, and
parallel analysis of NFAT5-deficient cells, as we have
shown here, would ensure that the measured reporter
activity is derived from NFAT5 rather from NFATc. In vivo,
however, calcineurin inhibitors might complicate the
interpretation of results due to side effects such as nephro-
toxicity, which might affect sodium and water homeosta-
sis in the organism [41] and indirectly perturb the
regulation of NFAT5 and NFATc proteins. Crosses
between 9xNFAT-Luc mice and tissue-specific conditional
knockout for calcineurin or NFAT proteins might prove
useful to study these factors in vivo.
Our experiments, together with independent results from
the literature, revealed some heterogeneity in the sensitiv-
ity of NFAT5 transcriptional activity to pharmacological
inhibitors. Hypertonicity-induced activation of NFAT5 in
T lymphocytes was substantially downregulated by the
PI3-kinase and PIKK inhibitors wortmannin and
Table 2: Hypertonicity threshold required to activate the endogenous 9xNFAT-Luc reporter in transgenic lymphocytes.
9xNFAT-Luc reporter activity (RLU)
Preactivation with ConA + IL2 Stimulus Experiment # 1 Experiment # 2 Experiment # 3 Experiment # 4
24 hours 300 mOsm/kg (isotonic) 398 446 761 662
340 mOsm/kg 295 673 1628 690
360 mOsm/kg 1254 933 1648 944
380 mOsm/kg 11468 1622 6060 2353
400 mOsm/kg 38768 22808 11061 6494
PMA + ionomycin (isotonic) 7039 20428 12081 6647
48 hours 300 mOsm/kg (isotonic) 257 351 329 210
340 mOsm/kg 159 397 441 311
360 mOsm/kg 205 327 567 226
380 mOsm/kg 1118 1121 1204 1258
400 mOsm/kg 7105 7997 1891 3291
PMA + ionomycin (isotonic) 2079 19702 1803 3638
72 hours 300 mOsm/kg (isotonic) 155 356 113 146
340 mOsm/kg 136 357 131 214
360 mOsm/kg 128 342 196 99
380 mOsm/kg 188 379 260 148
400 mOsm/kg 288 467 458 288
PMA + ionomycin (isotonic) 11359 22321 2389 1511
Transgenic 9xNFAT-Luc splenocytes were activated with concanavalin A plus IL2 during 24 to 72 hours in isotonic medium, and then exposed to 
hypertonicity, or stimulated with PMA plus ionomycin for 24 hours. Luciferase activity is represented as relative light units per second (RLU) after 
normalization with endogenous lactate dehydrogenase.BMC Molecular Biology 2008, 9:13 http://www.biomedcentral.com/1471-2199/9/13
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LY294002. This result agreed with previous reports using
Jurkat T cells and HEK293 cells [10,11]. We also found
that inhibition of PIKK impaired the upregulation of
NFAT5 expression by hypertonicity in non-transformed
lymphocytes and MEF. ATM and other PIKK regulate the
nuclear translocation of NFAT5 [42], but their involve-
ment in upregulating NFAT5 expression had not been pre-
viously documented. These observations indicate that
PIKK regulate different layers of NFAT5 function.
With regard to other pathways, we found that activation
of NFAT5 was inhibited by two independent p38 inhibi-
tors, SB203580 and SB202190. Reports indicate that p38
might not be a universal regulator of NFAT5, since Kultz
et al., showed that a dominant negative construct of
Hypertonicity threshold required to activate the 9xNFAT-Luc reporter in different cell types Figure 4
Hypertonicity threshold required to activate the 9xNFAT-Luc reporter in different cell types. A) Luciferase 
activity in 9xNFAT-Luc transgenic splenocytes treated during 24 hours with hypertonicity or PMA plus ionomycin, after having 
been preactivated with concanavalin A plus IL2 during 24 hours, 48 hours or 72 hours. One representative experiment is 
shown out of three performed independently (see Table 2). B) Luciferase activity in 9xNFAT-Luc transgenic bone marrow-
derived macrophages from NFAT5+/+ and NFAT5-/- mice exposed to increasing hypertonicity levels during 24 hours. Mean ± 
S.D of two independent experiments is shown. C) Luciferase activity in 9xNFAT-Luc transgenic bone marrow-derived macro-
phages exposed to increasing hypertonicity levels during 24 hours, in the absence or presence of FK506 (100 nM). Mean ± S.D 
of three independent experiments is shown. D) Luciferase activity in 9xNFAT-Luc transgenic mouse embryo fibroblasts 
exposed to increasing hypertonicity levels during 24 hours. Mean ± S.D of three independent experiments is shown. N.S.: non 
statistically significant.
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MKK3 failed to inhibit the NFAT5-dependent reporter
ORE-Luc in PAP-HT25 rabbit renal medullary cells [12],
whereas Ko et al., showed that both a dominant negative
p38 construct and SB203580 effectively inhibited the
same reporter in NIH3T3 and MEF [7]. Tsai et al., found
that a dominant negative p38 also inhibited the NFAT5-
regulated TauT and Hsp70 promoters in nucleus pulposus
cells [9]. The same report also showed that a dominant
negative ERK construct and the ERK inhibitor PD98059
partially inhibited NFAT5, whereas we found that activa-
tion of NFAT5 in primary mouse T cells was insensitive to
PD98059. H89 had been reported to partially inhibit
NFAT5 transcriptional activity in the HepG2 hepatocellu-
lar carcinoma cell line [8], and we obtained similar results
in T cells. The JNK inhibitor SP600125 did not impair the
activation of the 9xNFAT-Luc reporter in T cells (not
shown), in agreement with previous reports showing that
neither SP600125 [9] nor inhibition of JNK with a domi-
Sensitivity of NFAT5 transcriptional activity and expression to pharmacological inhibitors Figure 5
Sensitivity of NFAT5 transcriptional activity and expression to pharmacological inhibitors. A) Transgenic 
9xNFAT-Luc splenocytes preactivated during 24 hours with concanavalin plus IL2 were treated with hypertonicity (400 
mOsm/kg, 24 hours) in the absence or presence of FK506 (100 nM), SB203580 or SB202190 (both at 10 µM), PD98059 (10 
µM), H89 (2 µM), wortmannin (0.5 µM), or LY294002 (LY). Luciferase activity in the upper panel (mean ± S.D of three inde-
pendent experiments) is shown as percentage of the activity in the absence of inhibitors (100%). Western blotting in the lower 
panelshows NFAT5 and pyruvate kinase expression. B) Transgenic MEF were stimulated for 8 or 24 hours with hypertonicity 
(460 mOsm/kg) in the absence or presence of SB203580 (10 µM) or LY294002 (LY). Luciferase activity is shown is the upper 
panel (mean ± S.E.M of three independent experiments). NFAT5 and pyruvate kinase expression are shown in the lower panel.
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nant negative SEK1 construct [12] inhibited NFAT5 in
other cell types. We interpret our results with inhibitors
cautiously, as some might inhibit more than one single
kinase (see [43,44], and [45] for a recent update). None-
theless, our profiling of the sensitivity of NFAT5 to phar-
macological inhibitors in T cells, together with previous
reports, supports the notion that activation of NFAT5 by
hypertonicity involves distinct combinations of regulators
in different cell types. Unravelling the identity of kinases
and properties of NFAT5-regulatory pathways in specific
cell types would help to understand the relevance of
osmotic stress responses in mammals.
While it is clear that the osmoprotective function of
NFAT5 is critical in the renal medulla, a physiologically
hypertonic environment [16], many other cell types can
also express and activate this factor when exposed to
hypertonic stress. However, its activation threshold under
physiological or pathological tonicity conditions in differ-
ent cell types is largely unknown. Our experiments show
that activated T lymphocytes are sensitive to moderate
increases in extracellular tonicity, and could induce
NFAT5 expression at relatively low levels of hypertonicity
(330 mOsm/kg), and detectable transcriptional activity of
this factor at 360–380 mOsm/kg, which increased sharply
at 400 mOsm/kg. Tonicity levels in the 360–400 mOsm/
kg range have been recorded in the plasma of patients
with osmoregulatory disorders and in aquaporin and
vasopressin receptor-deficient mice [28-37]. The hyperto-
nicity level required to stimulate the 9xNFAT-Luc reporter
in lymphocytes varied with their activation state. The
reporter did not respond to hypertonicity in resting lym-
phocytes, showed a robust response to 380 and 400
mOsm/kg in T cells that had been exposed to mitogens for
24 hours, and became less responsive in cells cultured
during 48 to 72 hours. T cell activation by mitogens or
antigen receptor causes a dramatic increase in biogenesis,
cell growth and gene expression during the first 24–48
hours, that precedes the entry of the lymphocyte in a series
of cell division rounds [46,47]. That T cells display a
greater sensitivity to hypertonicity and a stronger NFAT5
transcriptional response in the first stages of their activa-
tion is likely relevant to ensure their function under
potentially harmful osmotic stress conditions. In this
regard, exposure of fresh NFAT5-deficient T cells to 370
mOsm/kg during the first 3 days of antigen receptor-
induced activation reduced their proliferation rate by
more than 60%, whereas normal lymphocytes were not
affected [17]. Altogether, these observations indicate that
pathologic elevations of the extracellular tonicity rapidly
activate the expression and transcriptional activation of
NFAT5 in lymphocytes to ensure an appropriate osmo-
protective response.
Activation of the reporter in macrophages and MEF
required higher tonicity levels than in lymphocytes. It is
intriguing that diverse cell types appear to require differ-
ent hypertonicity levels to activate NFAT5-mediated tran-
scriptional responses. While lymphocytes, as shown here
and by Go et al. [17], and possibly neurons [22] and mac-
rophages can respond to hypertonicity levels that may
occur in certain pathologic conditions, other cells such as
fibroblasts require a hypertonicity threshold that is
unlikely to be found out of the renal medulla. Investigat-
ing the gene expression programs regulated by increasing
levels of hypertonicity in different cell types might pro-
vide clues about the biological relevance of this response.
Conclusion
Our study indicates that the 9xNFAT-Luc reporter can be
selectively activated by NFAT5 or NFATc proteins in a
stimulus-specific manner. Transgenic 9xNFAT-Luc mice
might be used to analyze not only NFATc proteins, but
also the transcriptional activation of NFAT5 by hyperto-
nicity and its regulation by signaling pathways in primary
cells and tissues. It was known that NFAT5 is fundamental
to sustain cell function and viability in the renal medulla,
a naturally hypertonic environment. Here we show that
the expression and transcriptional activation of NFAT5 in
lymphocytes are remarkably sensitive to pathologic dis-
turbances of the extracellular tonicity. Similar studies
using this transgenic mouse model combined with other
approaches should help to elucidate the role of NFAT5 in
response to physiopathological tonicity changes in differ-
ent types of mammalian cells.
Methods
Reagents
Phorbol 12-myristate 13-acetate (PMA), the calcium
ionophore ionomycin, FK506, and the protein kinase
inhibitors H89, LY294002, PD98059, SB202190,
SB203580, SP600125 and wortmannin were purchased
from Calbiochem (Darmstadt, Germany).
Cell culture
The human T cell line Jurkat (Clone E6-1, American Type
Culture Collection, #TIB 152) was kindly provided by Jer-
emy Luban (Columbia University College of Physicians
and Surgeons, New York, NY) and maintained in Dul-
becco's modified Eagle's Medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 50 µM β-mercap-
toethanol (Gibco, Pasley, UK). Mouse embryonic fibrob-
lasts (MEF), bone marrow-derived macrophages
(BMDM), and mouse T lymphocytes were cultured in the
above medium plus 100 µM non-essential amino acids
and penicillin-streptomycin (Gibco).BMC Molecular Biology 2008, 9:13 http://www.biomedcentral.com/1471-2199/9/13
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Mouse embryonic fibroblasts, macrophages, and 
lymphocytes
9xNFAT-Luc mice (line 15.1) [24] in FVB background,
and NFAT5+/- mice [16] in 129Sv background were bred
and maintained under specific pathogen-free conditions,
and handled according to institutional guidelines (PRBB
Animal Care and Use Committee). MEF were prepared
from 13.5-day embryos using the NIH3T3 protocol to
obtain spontaneously immortalized cells [16]. Bone mar-
row-derived macrophages (BMDM) were obtained by cul-
turing femur and tibia marrow cell suspensions in L-929
cell-conditioned medium as previously described [48].
Mouse L-929 cells were kindly provided by Antonio
Celada (Barcelona Institute for Biomedical Research, Bar-
celona, Spain). Briefly, bone marrow cells were cultured
(37°C, humidified 5% CO2 atmosphere) in plastic tissue
culture dishes (150 mm) in 40 ml of DMEM containing
10% FBS and 30% L-929 cell-conditioned medium as a
source of M-CSF. Penicillin/Streptomycin were added.
After 7 days of culture, macrophages were obtained as a
homogenous population of adherent cells (>95%
CD11b+). No differences were observed in the expansion
and differentiation of macrophages derived from NFAT5+/
+ or NFAT5-/- mice (not shown). Splenocytes and thymo-
cytes were isolated from 8–12 weeks old mice. Proliferat-
ing T cells were obtained by activating splenocytes with
2.5 µg/ml concanavalin A (Sigma, Steinheim, Germany)
plus 25 ng/ml of recombinant human IL2 (Proleukin,
Chiron, Amsterdam, The Netherlands) for three days. T
lymphocytes (>95% CD3+) were cultured at 1 × 106 cells/
ml in fresh medium supplemented with IL2 for an addi-
tional 24 hours. Cells growing in IL2-supplemented isot-
onic medium (300 mOsm/kg) were treated with 10 nM
PMA plus 0.3 µM ionomycin, or hypertonicity, by adding
NaCl. Osmolarity of the culture medium was measured in
a Fiske One-Ten Osmometer (Fiske Associates. Norwood,
MA, USA). Over an isotonic baseline of 300 mOsm/kg,
addition of 30 mM NaCl raised the osmolality to 360
mOsm/kg, 40 mM NaCl to 380 mOsm/kg, 50 mM NaCl
to 400 mOsm/kg, and 90 mM NaCl to 480 mOsm/kg.
DNA constructs
The luciferase reporters 9xNFAT-Luc [24] and ORE-luc
have been described [3]. Expression vectors for NFAT5
(Myc-NFAT5-GFP) [2], NFAT5 dimerization domain
(DD5-GFP) [3], and the NFATc inhibitory peptide VIVIT
(VIVIT-GFP) [25] were described. pEGFP-N1 (Clontech,
Palo Alto, CA, USA), pTK-Renilla (Promega, Madison, WI,
USA), and pBlueScript SK+ (pBSK+) (Stratagene, La Jolla,
CA, USA) are available commercially.
Transfections and reporter assays
Jurkat T cells were transfected by electroporation (Bio-Rad
Gene Pulser. Bio-Rad, Hemel Hampstead, UK) [49], with
luciferase reporter plasmids (0.3 µg/106 cells) and TK-
Renilla (0.1 µg/106 cells), together with either pEGFP-N1
(1 µg/106 cells), VIVIT-GFP (2 µg/106 cells), or DD5-GFP
(2  µg/106 cells). MEF were transfected by the calcium-
phosphate method in 10-cm plates with luciferase
reporter (1 µg/plate) plus TK-Renilla (1 µg/plate), and
either pBSK+ (22 µg/plate) or NFAT5 expression vector
(22 µg/plate). Transfected cells were stimulated in isot-
onic medium (300 mOsm/kg) with either 20 nM PMA
plus 1 µM ionomycin or subjected to hypertonic condi-
tions as indicated in figure legends. FK506 was used at
100 nM. Luciferase and Renilla were measured with the
Dual-luciferase reporter system (Promega) with a
Berthold FB12 luminometer (Berthold, Pforzheim, Ger-
many). When reporters were transfected in cell lines, luci-
ferase activity was normalized to Renilla and endogenous
lactate dehydrogenase (LDH), which was proportional to
the number of viable cells [49]. Luciferase activity in trans-
genic cells was normalized to endogenous LDH in the
same lysate, measured with the CytoTox 96 Non-Radioac-
tive Cytotoxicity Assay (Promega).
Western blot
Cell lysates, Western blotting, and enhanced chemilumi-
nescent detection (Supersignal West Pico Chemilumines-
cent Substrate, Pierce, Rockford, IL, USA) were done as
described [3]. PVDF membranes were probed with anti-
NFAT5 (catalog number: PA1-023, Affinity Bioreagents;
Golden CO, USA). Anti-Pyruvate kinase (AB1235; Chemi-
con, Hampshire, UK) was used as a protein loading con-
trol.
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